(Total Views: 318)
Posted On: 05/13/2018 5:54:25 PM
Post# of 63818
Highlights of QBL subsidiary on MMJ DEVELOPMENT.
• The board has an effective mix of both pharmaceutical and cannabis expertise working on MCL’s drug development strategy
• MCL’s strategy will position Canntab as a reliable and medical based ‘product of choice’
• Revenue is targeted in Australia in 2018 via Canntab sales under the Special Access Scheme
• MCL is targeting broader adoption in pain relief through the clinical trial process
Here you have a opportunity to take advantage on facts and info from QBL. Like the QBL on ASX website chapter, who can provide verified facts; here is regulated on-line stockbrokers suggestion, no games info and a good sum up. Voluntary suspension is requested regarding a significant and strategic acquisition by QBL’s subsidiary Medical Cannabis Limited until next week. Contact information to the QBL Investor service, who can reply on questions.
https://www.queenslandbauxite.com/
• The board has an effective mix of both pharmaceutical and cannabis expertise working on MCL’s drug development strategy
• MCL’s strategy will position Canntab as a reliable and medical based ‘product of choice’
• Revenue is targeted in Australia in 2018 via Canntab sales under the Special Access Scheme
• MCL is targeting broader adoption in pain relief through the clinical trial process
Here you have a opportunity to take advantage on facts and info from QBL. Like the QBL on ASX website chapter, who can provide verified facts; here is regulated on-line stockbrokers suggestion, no games info and a good sum up. Voluntary suspension is requested regarding a significant and strategic acquisition by QBL’s subsidiary Medical Cannabis Limited until next week. Contact information to the QBL Investor service, who can reply on questions.
https://www.queenslandbauxite.com/
(0)
(0)
Robert
